Vision. Expertise. Success.
AbbVie Contract Manufacturing partners with companies across the globe to develop, scale and manufacture pharmaceutical products and bring them successfully to market.

Drawing on more than four decades of success as the manufacturing division of AbbVie, we have the depth of experience and the technical knowledge to navigate issues and deliver the innovative solutions customers need. We are much more than a CMO – we are your partner for success.

With foresight, scientific expertise, and passion we anticipate the technical and compliance challenges along the entire pharmaceutical development journey through to commercialization. We see the complete picture to deliver our customer's vision.

With full access to global state-of the-art facilities and world-class talent, our customers have come to depend on our service and quality to deliver real-world results.

Visit abbviecontractmfg.com for more information.

Adare Pharma Solutions is a global technology-driven CDMO providing end-to-end integrated services, from product development through commercial manufacturing and packaging, with small molecule expertise focusing on oral dosage forms. Our specialized technology platforms provide taste masking, controlled release, solubility enhancement, and patient-centric dosing solutions. We have developed and manufactures more than 65 products sold by customers worldwide.

We have the expertise and proven track record to guide projects from clinical research stages through optimization, validation, and approval. We operate seven facilities in the US and Europe, equipped to facilitate efficient drug product development and manufacturing, maintaining excellent environmental conditions compliant with US and EU cGMP regulations.

Adare has dedicated high potency GMP manufacturing and development areas. Our in-house regulatory and quality teams have a proven global track record, assuring our clients that products we manufacture are provided with the highest relevant standards for patient care.

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.
The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) BioChaperone® for the stabilization and enhancement of peptide formulations and combinations; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoXLong™, a long-acting peptide platform.
Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).

We are Ardena, a reputable contract partner delivering drug development, manufacturing, logistics and (bio)analytical services to pharmaceutical customers globally. In parallel, we work with you to compile your regulatory dossier and to fast track your product towards compliance. Every day, we guide companies through the hurdles and challenges of drug development. Our integrated service offering helps to streamline the drug's progress to clinic and beyond. Ardena is your one source contractor for the chemical and pharmaceutical development of your valued compounds. In parallel, we provide you with full product analytical and bioanalytical support during development. Our dossier-centric approach makes a difference. We work with you to compile your regulatory dossier in parallel with drug development, saving you time, identifying hurdles and fast-tracking your product to compliance. We are experts in writing and formatting supporting CMC documentation.

Asahi Kasei is a highly diversified Japanese supplier of high-performance materials for various industries, including automotive, energy, electronics, housing and health care. In the fields of pharma- and nutraceuticals, we offer functional excipients. For many decades Asahi Kasei stands for quality, reliability and performance and is dedicated to “Creating for Tomorrow”.

Our key product is Ceolus, functional grades of microcrystalline cellulose (MCC) with outstanding compactability and flowability due to a special particle structure. This allows for avoiding typical formulation challenges like tablet mass segregation, capping, slow/fast disintegration, low tablet hardness or the changing of the API structure. Celphere, Asahi Kasei’s MCC spherical cores allow the combination of incompatible APIs in one tablet, achieve different release profiles and improve the acceptability of products. Special grades of our pregelatinized starch PC-10 can be applied for the protection of moisture sensitive APIs in the formulation.

Our functional excipients prove to be solutions to our customer’s daily challenges.

Ashland works alongside formulators to advance drug-specific delivery platforms with an industry-leading portfolio of pharmaceutical excipients and technical expertise including superior polymer technology and systems for optimum bioavailability.

For over 50 years, Ashland has created value for customers through applications knowledge, technical support, and a powerful product portfolio. The company offers real-time solutions based on superior binder, film coating, solubilizer, disintegrant, rheology control, cyclodextrins and modified-release technologies.

A team of technical experts at global R&D centers provide formulation development support for conventional and potent compounds as well as controlled substances to offer tailored solutions that address solubility challenges.

During this event, Ashland will showcase polymer solutions for extended release injectable depot strategies including ViatelTM bioresorbable polymers. This portfolio includes 72 GMP grades of lactide, glycolide and caprolactone copolymers as well as a customized polymer platform which supports formulators to solve complex processing, stability and delivery challenges.

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. With 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.

Focusing On Your Formulation Needs

BASF produces excipients and active ingredients of outstanding quality and performance. With our unique expertise in polymer chemistry, our research & development capabilities and our clear commitment to developing excipients, BASF has continuously created solutions that contribute to your success and to more efficient pharmaceuticals. We deliver value added functional solutions to your formulation challenges by leveraging our expertise in delivery systems and related technologies. Our team of experienced industry specialists support you in developing effective, reliable formulations – giving you a vital advantage in a highly competitive market.

Our Platforms – Your Access To BASFs Solution Offer

BASF has been committed to the pharmaceutical industry since we introduced our original Kollidon® in the early 20th century. Since then we have continuously expanded our solution offer. Today we solve unmet formulation needs and offer intelligent solutions for today and tomorrow's challenges in drug formulation. Our four dedicated solution platforms based on current pharmaceutical market needs help you to find what you are looking for – faster than ever before. We can help with formulation challenges related to Instant and Modified Release, Solubilization, Skin Delivery, Softgels and Biologic Solutions

BIONANOPHARMA, part of the Insud Pharma Group, is a drug delivery company with an EU-GMP–approved facility specializing in electronebulization and electrospinning.

Our patented technology platform enables tailored drug release profiles in fiber or powder form, using room-temperature processing—ideal for thermally sensitive biologics (mAbs, ADCs, proteins, enzymes, RNA, vaccines) and complex small molecules (oligonucleotides, peptides).

Fiber formats support buccal, sublingual, transdermal, and ophthalmic patches, as well as orally dissolving films and inserts. Our powders are engineered to enhance the bioavailability of BCS Class II, III, and IV APIs, and are suitable for oral dosage forms, inhalation, nasal delivery, and long-acting injectables.

The process is fully scalable, uses commercially available pharma-grade excipients, and supports batch sizes from milligrams to tonnes—ensuring flexibility from early development to commercial production.

Catalent specialises in comprehensive development, analytical and bioavailability enhancement from candidate selection to fully integrated solutions, to help get customers’ drugs to clinic faster. Using a rigorous, data-driven scientific approach, API-sparing techniques and advanced formulation technologies within a global network, Catalent helps solve complex challenges to accelerate drug development.

Codis is a global CDMO with world class manufacturing capabilities and deep expertise in spray drying, amorphous solid dispersions (ASD), and particle engineering technologies. Formed through the integration of Particle Dynamics in the US and the Haverhill, UK facility previously operated by EUROAPI, Codis unites decades of regulatory excellence, technical innovation, and commercial manufacturing strength under one brand. Our Haverhill site located near Cambridge, UK, is a purpose built, continuously upgraded pharmaceutical manufacturing facility with a long standing track record in global supply. Specializing in complex APIs, co processed excipients, and spray dried amorphous dispersions, the site operates with full cGMP compliance, robust environmental controls, and a strong safety culture.

Corealis Pharma offers complete formulation development and clinical supply manufacture of pharmaceutical oral solid dosage forms for US, European and Canadian submissions. Each project is different and Corealis experts select the most suitable formulation and manufacturing process train for each drug substance as per its intended application. They have in-house access to well-equipped, state of the art R&D and GMP compliant operations such as API characterization, spray drying, hot melt extrusion, solid dispersion, high shear granulation, fluid-bed granulation/ drying/ coating, roller compaction, melt granulation, extrusion/spheronization, pan coating, tableting, encapsulation, packaging, patient kits preparation, warehousing, distribution and analytical services. This means that when Corealis professionals commit to a delivery date and budget, they have all the tools and resources needed to stand by their commitments and the ability to adjust quickly to any changes that may occur in the execution of a project.

Coriolis Pharma is a globally active, science driven contract research and development organization (CRDO) and a premier partner for drug product development, analytical services, and manufacturing across a broad range of biological therapeutic modalities. With deep expertise in both liquid and lyophilized drug products, Coriolis’ scientists design and execute platform and customized services that accelerate and de risk client programs from the very beginning and throughout the entire product lifecycle.

Coriolis Pharma distinguishes itself through scientific excellence, innovative analytical approaches, and a profound understanding of formulation and drug product development. The company is headquartered in Martinsried, Germany, and operates a U.S. facility in the Research Triangle of North Carolina.

Croda Pharma is a leading partner for the development of excipients and the supply of high purity materials for pharmaceutical formulations. The company is focused on empowering biologics drug delivery, through its adjuvant systems, small molecule, protein, and nucleic acid delivery platforms. With a wide range of solutions for both human and animal health markets, the pharmaceutical portfolio is unsurpassed in its excellence. Croda Pharma’s products, along with its in-house formulation and regulatory expertise, allows the company to meet its customers’ most demanding formulation needs. The company is committed to enabling the next generation of drug delivery systems.

Curia’s network of sterile drug product facilities support partners from formulation development to commercial manufacturing in various formats including vials, pre-filled syringes, and cartridges. With over 30 years of experience formulating both large and small molecules for injection, you can rely on Curia.

DFE Pharma is a global leader in the development, production and supply of high-quality functional excipients for use in the pharmaceutical, biopharmaceutical, and nutraceutical industries for respiratory, OSD, ophthalmic and parenteral formulations.

Our excipients play an essential role as fillers, binders, disintegrants, and in stabilizing active ingredients. With more than a century of experience and around 450 people worldwide, we serve over 5,000 customers in 100+ countries. Headquartered in Goch, Germany, DFE Pharma is committed to supporting (bio)pharmaceutical and nutraceutical companies to improve patient’s lives, driven by our purpose: Your medicines, and our solutions. Moving to a healthier world.

As innovators in nutrition, health, and beauty, we reinvent, manufacture, and combine vital nutrients, flavors, and fragrances for the world’s growing population to thrive.
In the Biomedical division, we serve as a committed partner in driving sustainable innovation in healthcare, from spark to solution. Our biomaterial products, customized solutions and expert services are recognized for their unmatched quality, reliability, and performance worldwide.
Together, we bring progress to life every day, everywhere, for billions of people.To learn more, visit

Since 1880, Gattefossé has developed and manufactured high-quality lipid excipients for human and animal health. Our oral excipients offer solubility/bioavailability enhancement, sustained release, lubrication, and taste-masking. We also provide solubilizers, penetration enhancers, emulsifiers, and viscosity enhancers for improved topical formulations, as well as suppository and pessary bases. All Gattefossé products are backed by comprehensive safety, quality, and regulatory documentation to support your formulation and manufacturing needs. To accelerate development, our team of highly trained experts offers hands-on support through four Technical Centers of Excellence located in France, China, India, and the United States.

Hovione offers customized services and innovative solutions from drug substance to drug product, with all activities performed at the same site. Hovione provides a fully integrated service for clinical and small commercial scale complex drug product development and manufacturing as well as formulation development for highly sophisticated inhalation and other formulations both for small molecules and biologics. As the Leader in Commercial Spray Drying, Hovione can handle projects from early-phase development to commercial and accelerates your time to market. Our particle engineering technologies can address challenges in solubility enhancement, lung delivery, modified release and taste-masking applications and can handle highly potent compounds. For biopharmaceuticals Hovione is investing by partnering in specialized particle engineering technologies, namely spray drying, aseptic spray freeze drying, nanoparticles and microemulsions. We do well what is difficult, to give our customers what they cannot find elsewhere

InnoCore Pharmaceuticals is a biopharmaceutical drug delivery company specialized in the development of long-acting injectables (LAI) for the treatment of several (chronic) diseases e.g. oncology, pain, atherosclerosis, macular degeneration, CV, osteoarthritis. Using biodegradable polymers for microspheres, gels and implants (including ISFI) we have a unique platform to control sustained drug delivery of small molecules, peptides and proteins (including mAbs) from days, weeks to months (6).

Based on 60 years of experience in the development and manufacturing of scientific instruments, KNAUER also offers custom engineering of equipment for the laboratory and for GMP production.

The company’s most recent development in this field – lipid nanoparticles (LNP) production systems – have enabled the large-scale manufacturing of mRNA-based vaccines to fight the Corona pandemic.

Traditionally, KNAUER is best known for its high-precision liquid chromatography systems (HPLC and FPLC) and related components. The systems are used to analyze samples for ingredients and impurities and determine their quantities, both in the laboratory and in process analysis. The systems can also purify value substances such as active pharmaceutical ingredients on a laboratory scale.

KNAUER’s valves, pumps, detectors, and other components are also used for tasks such as high-pressure dosing and various flow detection tasks in different applications. OEM manufacturing LC components for other suppliers is an important part of KNAUER’s business.

Leukocare is a formulation development partner specializing in biologics, applying bioinformatics-driven preselection and empirical design to develop molecule-specific solutions. Our proprietary, data-guided approach accelerates identification of excipients and formulation parameters, reducing timelines and conserving drug substance.

Lonza Capsugel provides high-quality capsules and innovative solutions for oral drug delivery and inhalation. Lonza Capsugel's expertise supports the optimization of formulations, offering tailored technologies and services to advance pharmaceutical and nutraceutical development worldwide. Lonza Capsugel's global network includes complete supply chain, regulatory, quality and application support to meet your needs with capsule manufacturing facilities in North America, Europe, India, China and Japan. Lonza Capsugel offers full lifecycle development and manufacturing (CDMO) for oral and inhalation drug products.”

Find out more at www.lonza.com
Follow @Lonza on LinkedIn

As a trusted technology partner for the pharmaceutical industry, LTS develops and manufactures innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) as well as wearable drug delivery devices (“OBDS”). LTS´ commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 40 development projects targeting multiple disease indications. LTS’s innovation pipeline contains both partner-funded as well as proprietary, LTS-funded projects. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Microneedle Array Patches (“MAP”) for the transdermal delivery of small and large molecules, biological actives and vaccines. With its SorrelTM wearable drug delivery platform LTS offers patient friendly solutions for complex drugs delivery at home. Founded in 1984, LTS operates today from four sites: in Andernach, Germany, West Caldwell, NJ, USA, St. Paul, MN, USA and Netanya, Israel. LTS has also a representative office in Shanghai, China.

Lubrizol provides excipients that enhance the solubility and bioavailability of active ingredients. Apinovex™ Polymers are used for amorphous solid dispersions, improving the solubility of poorly soluble drugs. Apisolex™ Polymers enhance solubility in injectable formulations, offering high drug loading and stability.

Carbopol® Polymers are high molecular weight polyacrylic acid polymers used in various formulations for their thickening and stabilizing properties. We also supply a range of other ingredients listed on the FDA’s Inactive Ingredient Database (IID) that can help improve the feel and performance of topical pharmaceutical formulations.

Nanoform is an innovative nanoparticle medicine-enabling company that works together with global Pharma and biotech partners to devise solutions to complex formulation challenges. Nanoform’s multi-patented and scalable Controlled Expansion of Supercritical Solutions (CESS®) process can produce uniform nanoparticles as small as 10nm, facilitating transport even across biological barriers. As particles smaller than 100nm have significantly enhanced surface areas, this can increase drug dissolution rates and improve bioavailability, allowing drugs of poor solubility in the pharmaceutical pipeline to progress to clinical development. CESS® enables lower dosage and safer products to be developed with reduced side-effects and permits combination therapies, which would otherwise be prohibited by the large dosages of either drug. The award-winning technology is also ushering in a new era of ocular, pulmonary and transdermal drug delivery applications, along with enhanced delivery of drug particles across the blood-brain barrier.

Pfanstiehl Inc. is a cGMP Manufacturer of High Purity Low Endotoxin components such as Trehalose, Sucrose, Mannitol, Maltose, Galactose (non-animal), Mannose and Amino Acids such as L-Arginine, Histidine, Glutamine and Methionine for Biologics, Biosimilars, Vaccines, Cell Culture Media and Injectables (liquid & lyo) located in Waukegan Illinois USA. Pfanstiehl has been in operation since 1919, focusing on both Biopharmaceutical excipients / critical components & Pharmaceutical HPAPIs / APIs (generic and on contract manufacturing base). Pfanstiehl specializes in isolation, purification, custom synthesis and scale-up development of regulated, high purity and low endotoxin Injectable Formulation Ingredients, Pharmaceutical Intermediates and Active Pharmaceutical Ingredients, in gram to multi-ton commercial quantities.

PharmaCircle is a leading information provider to the life sciences industry, providing pipeline and products intelligence, business prospecting tools, curated formulation and component details, supply chain insights, and other information solutions to subscribers. PharmaCircle’s Drug Delivery Technology Reviews provide in depth comparative analysis on more than 9,000 drug delivery technologies and delivery devices, including strengths/limitations, patents, deals, and the products associated with the technologies.
To learn more, visit www.pharmacircle.com.

Pion Inc. offers unique instruments and services for informed drug and food formulation decisions, spanning R&D to manufacturing. Pioneering in vitro to in vivo tools, we optimize drug development and provide insights for pharmaceuticals and biopharmaceuticals. Our mission: expedite drug development, serving a global market with two decades of trusted expertise. Headquartered in Massachusetts, USA, and a UK office for global reach, Pion Inc. advances pharmaceuticals through innovation.

Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients.

Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast. Because humanity needs solutions, fast.

Roquette is a family-owned global leader in plant-based ingredients and a leading provider of pharmaceutical excipients. Founded in 1933, the company currently operates in more than 100 countries, through more than 30 manufacturing sites, has a turnover of around 5 billion euros, and employs around 10,000 people worldwide.

Life and nature have been our sources of inspiration for decades. All our raw materials are of natural origin. From them, we enable a whole new plant-based cuisine; we offer pharmaceutical solutions that play a key role in medical treatments; and we develop innovative ingredients for food, nutrition and health markets. We truly unlock the potential of nature to improve, cure and save lives.

Thanks to a constant drive for innovation and a long-term vision, we are committed to improving the well-being of people all over the world. We put sustainable development at the heart of our concerns, while taking care of resources and territories. We are determined to create a better and healthier future for all generations.

Sartorius BIA Separations develops and manufactures market-leading CIM® monolithic chromatographic columns for the purification and analysis of large biomolecules, such as viruses, plasmids, mRNA and LNPs, which are applied in cell and gene therapies. The company’s Cornerstone® Biomanufacturing Development Services are the result of more than 25 years of hands-on experience with the most challenging biopharmaceutical products and offer a comprehensive approach of integrated process development solutions and novel technology designed to improve the robustness and yield of large biomolecules production while improving the safety of therapeutic products. Sartorius BIA's technology for manufacturing-scale purification is already used in the production of the first commercialized advanced therapeutics; the company also has a keen presence with novel drug candidates in the clinical pipeline.

Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

Founded in 1990, Schrödinger has over 650 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn, or visit our blog, Extrapolations.com.

Seppic, an Air Liquide Healthcare company, has been a subsidiary of the Air Liquide Group since 1986. For over 75 years, Seppic has developed, manufactured, and marketed unique ingredients for cosmetic, nutraceutical, pharmaceutical, veterinary, and industrial products. Across the world, Seppic has created a vast team of women and men who love what they do in service to their customers, and to the health, well-being, and beauty of all.

As an expert in surfactants, polymers, and formulation, Seppic offers pharmaceutical excipients adapted to oral, topical, and parenteral routes of administration. Its ingredients range from film coatings for tablets to injectable solubilizers and polymers for dermopharmacy. For over 25 years, Seppic has also offered high-performance adjuvants for therapeutic vaccines. Now, our work has expanded to involvement in prophylactic vaccines.

SE Tylose is the distribution organization of Shin-Etsu Chemical Co., Ltd. Japan and SE Tylose, Wiesbaden Germany and is registered in Wiesbaden. It is located at the Industrial Park Kalle-Albert in Wiesbaden. Together with our distributors, we are the exclusive business partners for our customers and multi national key accounts in the pharmaceutical- and the food industry. SE Tylose manages a regional, centralized warehouse for all products to be able to supply the customers in Europe on short-term base whenever necessary. SE Tylose will manage logistic for customers in other regions independent from Shin-Etsu´s production sites. For our pharma customers we offer with our technical application lab the possibility to optimize their processes if required. Our products are covering a very wide range of applications and they fully comply with FDA, USP/NF, JP and EP requirements. Pharmaceutical Excipients: Cellulose ether excipient is a pharmacologically inactive substance used as a carrier for the active ingredients in medication. PHARMACOAT® – Water-Soluble Film Coating Agent METOLOSE® – Binder and Thickening Agent METOLOSE® SR – Sustained release agent for hydrophilic matrix system L-HPC – Disintegrant with Binding Properties, Multifunctional Excipient HPMCP – Enteric Coating Agent Shin-Etsu AQOAT® – Enteric Coating Agent, Solid Dispersion Polymer Tylopur® – Low- and high viscosity Hypromellose

Processing and packaging for a better life – this is what 5,800 Syntegon employees work for every day. Be it with individual machines, systems, or services, we help you – our customers in the global pharmaceutical and food industries – to improve people's lives. For that we look back on more than 160 years of experience. In the pharma sector, our intelligent solutions enable the safe and high-quality production, processing, filling, inspection, and packaging of your liquid and solid pharmaceuticals. In the food industry, our flexible and reliable technologies produce and package confectionery, dry food, frozen food, and dairy products. With 1,100 service experts and a comprehensive service portfolio throughout the entire machine lifecycle from spare parts management to digital line optimization, Syntegon lays the foundation for your smooth production processes. In everything we do, our more than 30 sites in almost 20 countries keep a firm eye on our impact on the environment and society. Syntegon is a leader in the development of sustainable packaging solutions, reduces the energy consumption of its machines and pursues ambitious goals to lower its emissions.

WuXi STA, an integrated part of WuXi AppTec, is an industry-leading pharmaceutical development and manufacturing capability and technology platform serving the life sciences industry with operations across North America, Europe and Asia. As an innovative Contract Development, and Manufacturing Organization (CDMO) for small molecule new drug development, WuXi STA offers our worldwide partners efficient, flexible, and high-quality solutions from preclinical to commercial uses.

At XEDEV, we support your product development journey by combining extensive formulation and process expertise with state-of-the art manufacturing capacity.

We specialize in formulation and process development for solid drug products. Leveraging our extensive expertise, we design customized solutions to meet the requirements of each customer, ensuring advanced and efficient outcomes. Furthermore, XEDEV provides manufacturing services for R&D and GMP batches, supporting PK, Tox, Phase I and II clinical studies. Our flexible production capabilities range from small-scale to large-scale batch productions, accommodating your specific needs.

At XEDEV, we pride ourselves on being more than a service provider – we’re an extension of your team. With strong communication and collaboration at the core of our approach, we ensure a seamless and productive partnership. Contact XEDEV today to learn more about how we can support your development and manufacturing needs.

Find out more at www.xedev.com.

Zerion Pharma A/S is a pharmaceutical company aspiring to transform the pharmaceutical landscape for the formulation of poorly soluble drugs that are currently not reaching their therapeutic potential.

The company was established in 2019 as a spinout from the University of Copenhagen based on a decade of research. Zerion Pharma has pioneered the Dispersome® technology that greatly enhances the solubility of poorly soluble, oral drugs and improves bioavailability and therapeutic options for patients.

The Dispersome® technology is based around a class of novel excipient, namely beta-lactoglobulin (BLG), to formulate poorly soluble small molecule drugs into stable amorphous drug delivery systems with a high drug load. By increasing solubility and dissolution rate, the Dispersome® platform aims at improving bioavailability and therapeutic outcomes and reducing adverse effects in patients. The Dispersome® technology is well accepted with no safety risks and is compatible with standard solid oral dosage form manufacturing.